Eoflow: Stayin' Alive [U.S. Court of Appeals Overturns $59.4 Mn Trade Secret Verdict Vs Insulet]
On 28 May, the the U.S. Court of Appeals completely overturned the $59.4 million trade secret verdict that Insulet had previously won against its South Korean rival, Eoflow (294090 KS).
This is likely to have a major positive impact on Eoflow and negatively impact Insulet, which earned $781.8 million from sales of the Omnipod, its flagship product, in 2025.
Eoflow’s shares trading has been temporarily suspended. Once it does start trading again, its share price is likely to APPRECIATE SEVERAL TIMES its current value.
